Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.73 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.73 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.73 |
| ▸ | VDR | P11473 | 8/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.69 |
| ▸ | PGR | P06401 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | CDC25A | P30304 | 1/20 | 0.69 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.69 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.69 |
| ▸ | DRD3 | P35462 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10888072 | 1.00 | ADORA3 (0.73) | ADORA3SLC6A2AGTR1VDRMAPT | |
| SCHEMBL27542722 | 0.91 | ADORA3 (0.76) | ADORA3SLC6A2AGTR1VDRMAPT | |
| SCHEMBL10597997 | 0.91 | ADORA3 (0.76) | ADORA3SLC6A2AGTR1VDRMAPT | |
| SCHEMBL11681017 | 0.91 | ADORA3 (0.76) | ADORA3SLC6A2AGTR1VDRMAPT | |
| SCHEMBL11681021 | 0.91 | ADORA3 (0.76) | ADORA3SLC6A2AGTR1VDRMAPT | |
| SCHEMBL5305802 | 0.91 | VDR (0.75) | ADORA3SLC6A2AGTR1VDRMAPT | |
| SCHEMBL3728240 | 0.91 | VDR (0.75) | ADORA3SLC6A2AGTR1VDRMAPT | |
| SCHEMBL11226670 | 0.91 | VDR (0.75) | ADORA3SLC6A2AGTR1VDRMAPT | |
| SCHEMBL11317373 | 0.91 | VDR (0.75) | ADORA3SLC6A2AGTR1VDRMAPT | |
| SCHEMBL4655326 | 0.90 | ADORA3 (0.75) | ADORA3SLC6A2AGTR1VDRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190422-A1 | A METHOD OF EXTENDING THE DOSE RANGE OF VITAMIN D COMPOUNDS | Wisconsin Alumni Research Foundation (US) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009026265-A1 | A METHOD OF EXTENDING THE DOSE RANGE OF VITAMIN D COMPOUNDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-02-26 | — | — | WO | disclosed |
| US-20080249068-A1 | Method of Extending the Dose Range of Vitamin D Compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2008-10-09 | — | — | US | disclosed |
| US-7259143-B2 | Method of extending the dose range of vitamin D compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-08-21 | — | — | US | disclosed |
| EP-1545549-A1 | A METHOD OF EXTENDING THE DOSE RANGE OF VITAMIN D COMPOUNDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040053813-A1 | Method of extending the dose range of vitamin D compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2004-03-18 | — | — | US | disclosed |
| WO-2004022068-A1 | A METHOD OF EXTENDING THE DOSE RANGE OF VITAMIN D COMPOUNDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2004-03-18 | — | — | WO | disclosed |
| US-6291444-B1 | Treatment of t-cell immunodeficiencies with vitamin D compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2001-09-18 | — | — | US | disclosed |
| EP-0401357-B1 | IMPROVING REPRODUCTIVE FUNCTIONS IN MAMMALS | WISCONSIN ALUMNI RES FOUND (US) | 1996-03-20 | — | — | EP | disclosed |
| EP-0549367-A1 | Method of treating milk fever disease in dairy cattle | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1993-06-30 | — | — | EP | disclosed |
| US-4594192-A | 2α-fluorovitamin D3 | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1986-06-10 | — | — | US | disclosed |
| WO-1982002893-A1 | 1 ALPHA,25-DIHYDROXY-2 BETA-FLUOROVITAMIN D3 | WISCONSIN ALUMNI RES FOUND (US) | 1982-09-02 | — | — | WO | disclosed |
| WO-1981003023-A1 | 1 ALPHA-HYDROXY-2 BETA-FLUOROCHOLECALCIFEROL | WISCONSIN ALUMNI RES FOUND (US) | 1981-10-29 | — | — | WO | disclosed |
| US-4254045-A | DERIVATIVES OF VITAMIN D3; FOR TREATMENT OF METABOLIC BONE DISEASES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1981-03-03 | — | — | US | disclosed |
| US-4254045-A | DERIVATIVES OF VITAMIN D3; FOR TREATMENT OF METABOLIC BONE DISEASES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1981-03-03 | — | — | US | disclosed |
| US-4254045-A | DERIVATIVES OF VITAMIN D3; FOR TREATMENT OF METABOLIC BONE DISEASES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1981-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249068-A1 | Method of Extending the Dose Range of Vitamin D Compounds | VDR, CASK, CYP24A1 | ADORA3 841/4885SLC6A2 4222/4885AGTR1 232/4885 |
| US-20040053813-A1 | Method of extending the dose range of vitamin D compounds | VDR, SOST, CASK | ADORA3 261/4885SLC6A2 3702/4885AGTR1 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.